BioNexus Gene Lab partners with Fidelion for liquid biopsy cancer monitoring.

BioNexus Gene Lab Corp. and Fidelion Diagnostics have signed a term sheet for a strategic cross-equity partnership, with BGLC acquiring a stake in Fidelion and securing exclusive commercial rights to Fidelion's VitaGuard MRD platform in Southeast Asia. The partnership aims to create long-term shared value in liquid biopsy cancer monitoring and AI-driven biotechnology. The transaction is subject to definitive agreements.

KUALA LUMPUR, Malaysia, July 02, 2025 — BioNexus Gene Lab Corp. (BGLC) and Fidelion Diagnostics Pte. Ltd. have announced a significant strategic cross-equity partnership aimed at revolutionizing liquid biopsy cancer monitoring and AI-driven biotechnology in Southeast Asia. The partnership, which is subject to the execution of definitive agreements, involves BGLC acquiring a strategic equity stake in Fidelion and securing exclusive commercial rights to Fidelion's VitaGuard™ minimal-residual-disease (MRD) platform across the region [1].

The VitaGuard™ platform is a groundbreaking technology developed by Tongshu Gene Biotechnology Co., Ltd. in China, which allows for the detection of cancer recurrence months before it shows up on a CT scan. This technology utilizes a simple blood draw to identify fragments of tumor DNA (ctDNA) circulating in the bloodstream, eliminating the need for invasive tissue re-biopsies and significantly reducing costs [1].

The partnership aims to create long-term shared value by combining BGLC's commercial network with Fidelion's innovative technology. BGLC's CEO, Sam Tan, stated, "This alliance is nothing short of a paradigm shift - the moment precision oncology gets its own 'DeepSeek-class' technology upgrade. By combining VitaGuard™ with our commercial network, we will deliver next-generation cancer care to 680 million people across Southeast Asia" [1].

Fidelion's CEO, Dr. Yan Linghua, added, "Our team in China spent years perfecting VitaGuard’s one-tube, high-fidelity chemistry. Building Fidelion for global commercialisation—and partnering with BGLC for Southeast Asia - creates the fastest possible path to scale. Together, we aim to shatter the cost-accuracy trade-off, bringing ultra-sensitive, AI-ready cancer surveillance to every clinic" [1].

The transaction is part of a broader trend in the Chinese biopharma sector, which has seen significant licensing deal-flow and venture capital investment over the past 18 months, referred to as the "China-Biotech Wave" [1]. The partnership is expected to open a multi-billion-dollar recurring market in Southeast Asia, where cancer incidence is projected to top 2.4 million new cases annually by 2030.

Forward-looking statements in this press release include the completion of the proposed transaction, anticipated regulatory approvals, commercial launch plans, and the expected benefits of the partnership. These statements are subject to risks and uncertainties that could cause actual results to differ materially [1].

References:
[1] https://www.stocktitan.net/news/BGLC/bio-nexus-gene-lab-corp-and-fidelion-diagnostics-announce-landmark-pyqpl7ccx7rx.html